- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06179654
Fisioterapia preoperatoria del suelo pélvico para minimizar la incontinencia urinaria de esfuerzo después de la enucleación de la próstata con láser de holmio
The purpose of this study is to allow us to assess the effectiveness (or success) of starting pelvic floor physical therapy (i.e. exercises for your pelvic muscles) prior to HoLEP (holmium laser enucleation of the prostate) surgery for enlarged prostates in order to manage or prevent urinary incontinence (i.e. leaking) after surgery (i.e. post-operatively). Your pelvic floor refers to the muscles under your bladder along your pelvic bones that prevent you from leaking urine or stool. Traditionally, pelvic floor physical therapy is started after surgery and continued until urinary continence (i.e. no leaking of urine) is regained. We want to assess if beginning pelvic floor physical therapy prior to surgery (and continuing afterwards) reduces the time required to regain urinary continence following HoLEP.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The incidence of benign prostatic hyperplasia (BPH) in men significantly increases with age and is estimated to impact over 80% of men 70 to 80 years of age. HoLEP is one of many treatments for BPH and associated lower urinary tract symptoms. Compared to other minimally invasive surgical techniques for treatment of BPH, HoLEP has been found to have superior outcomes and is a prostate size-independent procedure with excellent durability, high efficacy, and low complications rates. However, transient stress urinary incontinence (SUI) following HoLEP may last for several months after surgery and can lead to diminished patient quality of life during the recovery period. Measures to prevent or reduce post-operative SUI following HoLEP, including PFPT, may improve patient outcomes.
SUI is also commonly documented after radical prostatectomy (RP) for prostate cancer. The mechanism for incontinence in both RP and HoLEP is thought to at least partially be related to temporary weakness of the external urinary sphincter, which is part of the pelvic floor musculature. While it is unclear if post-operative PFPT alone reduces SUI for patients who have undergone RP, there is evidence that PFPT started pre-operatively and continued post-operatively can decrease SUI following RP.
The utilization of pre-operative PFPT for patients undergoing HoLEP to reduce post-operative SUI is currently not well documented. To date, only one study has demonstrated evidence that PFPT prior to HoLEP may improve continence at 3 months. However, the study included patients with a BMI significantly lower than average in the United States, utilized an unclear PFPT program, and had a relatively small median prostate size (~60 mL), which is important as studies have shown that prostate size can affect post-operative incontinence.
We propose a prospective randomized trial to investigate the efficacy of standardized pre-operative PFPT in reducing SUI and improving patient QoL following HoLEP. This study will help determine the role of pre-operative PFPT in the management of HoLEP associated SUI.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age: >=18 years of age
- Sex: male sex assigned at birth (needs to have a prostate)
- BMI: all BMI
- Ethnic background: all ethnicities
- Medical history: patients scheduled to undergo HoLEP for BPH/LUTS and associated complications (i.e. gross hematuria, retention, etc.).
Exclusion Criteria:
- Neurological disorders: patients with a history of a neurologic disorder that could affect muscle function, neurogenic bladder, lumbosacral spine pathology
- Specific urologic conditions: patients with pre-operative indwelling catheter, urethral stricture greater than 1 centimeter in length or requiring dilation/incision, indwelling ureteral stent
- History of pelvic radiation: patient with prior pelvic radiation will be excluded
- Patients unable to give consent
- Non-English speaking patients given the need for multiple surveys and telephone follow-ups.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Preoperative PFPT
This group of patients will be instructed to start pelvic floor physical therapy 1 month before surgery. |
Pelvic floor physical therapy to start before prostate surgery rather than after surgery. |
|
Sin intervención: Postoperative PFPT
This group of patients will be instructed to start pelvic floor physical therapy after surgery (standard of care). |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to continence
Periodo de tiempo: 6 months after surgery
|
Time to recover from transient postoperative stress urinary incontinence |
6 months after surgery
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Uroflow
Periodo de tiempo: 6 months after surgery
|
urine flow rate (milliliters/second) |
6 months after surgery
|
|
Post void residual
Periodo de tiempo: 6 months after surgery
|
Residual urine after voiding (milliliters) |
6 months after surgery
|
|
international prostate symptom score
Periodo de tiempo: 6 months after surgery
|
validated questionnaire on urination symptoms |
6 months after surgery
|
|
operative time
Periodo de tiempo: day of surgery
|
length of surgery (minutes) |
day of surgery
|
|
length of stay
Periodo de tiempo: 30 days after surgery
|
days of hospitalization after surgery |
30 days after surgery
|
|
catheter duration
Periodo de tiempo: 30 days after surgery
|
days with catheter after surgery |
30 days after surgery
|
|
infectious complications
Periodo de tiempo: 30 days after surgery
|
urinary tract infection complication after surgery |
30 days after surgery
|
|
emergency room visits
Periodo de tiempo: 30 days after surgery
|
number of emergency room visits related to surgery |
30 days after surgery
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades urogenitales masculinas
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Trastornos de la micción
- Manifestaciones Urológicas
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Síntomas del tracto urinario inferior
- Retención urinaria
Otros números de identificación del estudio
- 23-1128
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .